Law360, New York (May 16, 2016, 4:07 PM EDT) -- The Federal Circuit on Monday affirmed a lower court's ruling that Glenmark infringed a Bayer Healthcare patent for the rosacea treatment Finacea, keeping Glenmark's planned generic version off the market until the patent expires in 2018.
The appeals court held that U.S. District Judge Sue L. Robinson did not err in any of the findings in her 2015 decision, including that Glenmark Pharmaceuticals Ltd. infringed under the doctrine of equivalents and that the patent is not invalid.
"The district court did a commendable job in rendering its detailed and thorough opinion," the Federal Circuit wrote. "Because we see no reversible error in...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!